Patient and Caregiver Assessment of the Benefits from the Clinical Use of Amyloid PET Imaging

Rafid Mustafa, Jared R. Brosch, Gil D. Rabinovici, Bradford C. Dickerson, Maria C. Carrillo, Bradley S. Glazier, Sujuan Gao, Martha Tierney, Keith N. Fargo, Mary Austrom, Susan De Santi, David G. Clark, Liana G. Apostolova

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Few studies to date have explored patient and caregiver views on the clinical use of amyloid positron emission tomography (PET). Methods: A 7-item questionnaire assessing patient and caregiver views (510 total respondents) toward amyloid PET imaging was advertised broadly through alz.org/trialmatch. Results: We received 510 unique responses from 48 US states, 2 Canadian provinces, the Dominican Republic, and Greece. Both patients and caregivers indicated that they would want to receive amyloid imaging if offered the opportunity. Over 88% of respondents had a positive response (∼10% with neutral and 2% with negative responses) to whether amyloid PET should be offered routinely and be reimbursed. Such information was felt to be useful for long-term legal, financial, and health care planning. Respondents identifying with early age cognitive decline (younger than 65 y) were more likely to explore options for disability insurance (P=0.03). Responders from the Midwest were more likely to utilize information from amyloid imaging for legal planning (P=0.02), disability insurance (P=0.02), and life insurance (P=0.04) than other US regions. Discussion: Patients and caregivers supported the use of amyloid PET imaging in clinical practice and felt that the information would provide significant benefits particularly in terms of future planning.

Original languageEnglish (US)
Pages (from-to)35-42
Number of pages8
JournalAlzheimer Disease and Associated Disorders
Volume32
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Amyloid
Positron-Emission Tomography
Caregivers
Disability Insurance
Dominican Republic
Life Insurance
Health Planning
Greece
Delivery of Health Care
Surveys and Questionnaires

Keywords

  • Alzheimer's disease (AD)
  • amyloid
  • caregiver
  • clinical use
  • patient
  • positron emission tomography (PET)

ASJC Scopus subject areas

  • Clinical Psychology
  • Gerontology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Mustafa, R., Brosch, J. R., Rabinovici, G. D., Dickerson, B. C., Carrillo, M. C., Glazier, B. S., ... Apostolova, L. G. (2018). Patient and Caregiver Assessment of the Benefits from the Clinical Use of Amyloid PET Imaging. Alzheimer Disease and Associated Disorders, 32(1), 35-42. https://doi.org/10.1097/WAD.0000000000000220

Patient and Caregiver Assessment of the Benefits from the Clinical Use of Amyloid PET Imaging. / Mustafa, Rafid; Brosch, Jared R.; Rabinovici, Gil D.; Dickerson, Bradford C.; Carrillo, Maria C.; Glazier, Bradley S.; Gao, Sujuan; Tierney, Martha; Fargo, Keith N.; Austrom, Mary; De Santi, Susan; Clark, David G.; Apostolova, Liana G.

In: Alzheimer Disease and Associated Disorders, Vol. 32, No. 1, 01.01.2018, p. 35-42.

Research output: Contribution to journalArticle

Mustafa, R, Brosch, JR, Rabinovici, GD, Dickerson, BC, Carrillo, MC, Glazier, BS, Gao, S, Tierney, M, Fargo, KN, Austrom, M, De Santi, S, Clark, DG & Apostolova, LG 2018, 'Patient and Caregiver Assessment of the Benefits from the Clinical Use of Amyloid PET Imaging', Alzheimer Disease and Associated Disorders, vol. 32, no. 1, pp. 35-42. https://doi.org/10.1097/WAD.0000000000000220
Mustafa, Rafid ; Brosch, Jared R. ; Rabinovici, Gil D. ; Dickerson, Bradford C. ; Carrillo, Maria C. ; Glazier, Bradley S. ; Gao, Sujuan ; Tierney, Martha ; Fargo, Keith N. ; Austrom, Mary ; De Santi, Susan ; Clark, David G. ; Apostolova, Liana G. / Patient and Caregiver Assessment of the Benefits from the Clinical Use of Amyloid PET Imaging. In: Alzheimer Disease and Associated Disorders. 2018 ; Vol. 32, No. 1. pp. 35-42.
@article{9e1156d556e6471bb46020c1ab381749,
title = "Patient and Caregiver Assessment of the Benefits from the Clinical Use of Amyloid PET Imaging",
abstract = "Introduction: Few studies to date have explored patient and caregiver views on the clinical use of amyloid positron emission tomography (PET). Methods: A 7-item questionnaire assessing patient and caregiver views (510 total respondents) toward amyloid PET imaging was advertised broadly through alz.org/trialmatch. Results: We received 510 unique responses from 48 US states, 2 Canadian provinces, the Dominican Republic, and Greece. Both patients and caregivers indicated that they would want to receive amyloid imaging if offered the opportunity. Over 88{\%} of respondents had a positive response (∼10{\%} with neutral and 2{\%} with negative responses) to whether amyloid PET should be offered routinely and be reimbursed. Such information was felt to be useful for long-term legal, financial, and health care planning. Respondents identifying with early age cognitive decline (younger than 65 y) were more likely to explore options for disability insurance (P=0.03). Responders from the Midwest were more likely to utilize information from amyloid imaging for legal planning (P=0.02), disability insurance (P=0.02), and life insurance (P=0.04) than other US regions. Discussion: Patients and caregivers supported the use of amyloid PET imaging in clinical practice and felt that the information would provide significant benefits particularly in terms of future planning.",
keywords = "Alzheimer's disease (AD), amyloid, caregiver, clinical use, patient, positron emission tomography (PET)",
author = "Rafid Mustafa and Brosch, {Jared R.} and Rabinovici, {Gil D.} and Dickerson, {Bradford C.} and Carrillo, {Maria C.} and Glazier, {Bradley S.} and Sujuan Gao and Martha Tierney and Fargo, {Keith N.} and Mary Austrom and {De Santi}, Susan and Clark, {David G.} and Apostolova, {Liana G.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/WAD.0000000000000220",
language = "English (US)",
volume = "32",
pages = "35--42",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Patient and Caregiver Assessment of the Benefits from the Clinical Use of Amyloid PET Imaging

AU - Mustafa, Rafid

AU - Brosch, Jared R.

AU - Rabinovici, Gil D.

AU - Dickerson, Bradford C.

AU - Carrillo, Maria C.

AU - Glazier, Bradley S.

AU - Gao, Sujuan

AU - Tierney, Martha

AU - Fargo, Keith N.

AU - Austrom, Mary

AU - De Santi, Susan

AU - Clark, David G.

AU - Apostolova, Liana G.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Few studies to date have explored patient and caregiver views on the clinical use of amyloid positron emission tomography (PET). Methods: A 7-item questionnaire assessing patient and caregiver views (510 total respondents) toward amyloid PET imaging was advertised broadly through alz.org/trialmatch. Results: We received 510 unique responses from 48 US states, 2 Canadian provinces, the Dominican Republic, and Greece. Both patients and caregivers indicated that they would want to receive amyloid imaging if offered the opportunity. Over 88% of respondents had a positive response (∼10% with neutral and 2% with negative responses) to whether amyloid PET should be offered routinely and be reimbursed. Such information was felt to be useful for long-term legal, financial, and health care planning. Respondents identifying with early age cognitive decline (younger than 65 y) were more likely to explore options for disability insurance (P=0.03). Responders from the Midwest were more likely to utilize information from amyloid imaging for legal planning (P=0.02), disability insurance (P=0.02), and life insurance (P=0.04) than other US regions. Discussion: Patients and caregivers supported the use of amyloid PET imaging in clinical practice and felt that the information would provide significant benefits particularly in terms of future planning.

AB - Introduction: Few studies to date have explored patient and caregiver views on the clinical use of amyloid positron emission tomography (PET). Methods: A 7-item questionnaire assessing patient and caregiver views (510 total respondents) toward amyloid PET imaging was advertised broadly through alz.org/trialmatch. Results: We received 510 unique responses from 48 US states, 2 Canadian provinces, the Dominican Republic, and Greece. Both patients and caregivers indicated that they would want to receive amyloid imaging if offered the opportunity. Over 88% of respondents had a positive response (∼10% with neutral and 2% with negative responses) to whether amyloid PET should be offered routinely and be reimbursed. Such information was felt to be useful for long-term legal, financial, and health care planning. Respondents identifying with early age cognitive decline (younger than 65 y) were more likely to explore options for disability insurance (P=0.03). Responders from the Midwest were more likely to utilize information from amyloid imaging for legal planning (P=0.02), disability insurance (P=0.02), and life insurance (P=0.04) than other US regions. Discussion: Patients and caregivers supported the use of amyloid PET imaging in clinical practice and felt that the information would provide significant benefits particularly in terms of future planning.

KW - Alzheimer's disease (AD)

KW - amyloid

KW - caregiver

KW - clinical use

KW - patient

KW - positron emission tomography (PET)

UR - http://www.scopus.com/inward/record.url?scp=85044323502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044323502&partnerID=8YFLogxK

U2 - 10.1097/WAD.0000000000000220

DO - 10.1097/WAD.0000000000000220

M3 - Article

C2 - 29140859

AN - SCOPUS:85044323502

VL - 32

SP - 35

EP - 42

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - 1

ER -